Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.12 AUD | +4.35% | +14.29% | +4.35% |
Mar. 26 | Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise | MT |
Mar. 20 | Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12% | MT |
Sales 2022 | 296K 197K | Sales 2023 | 1.45M 968K | Capitalization | 42.5M 28.28M |
---|---|---|---|---|---|
Net income 2022 | -8M -5.32M | Net income 2023 | -10M -6.66M | EV / Sales 2022 | 32 x |
Net cash position 2022 | 5.93M 3.94M | Net cash position 2023 | 5.18M 3.44M | EV / Sales 2023 | 25.7 x |
P/E ratio 2022 |
-1.47
x | P/E ratio 2023 |
-3.49
x | Employees | 27 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 91.45% |
1 day | +4.35% | ||
1 week | +14.29% | ||
Current month | -4.00% | ||
3 months | -27.27% | ||
6 months | +30.43% | ||
Current year | +4.35% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Baker
CEO | Chief Executive Officer | - | 20-01-01 |
Tim Luscombe
DFI | Director of Finance/CFO | - | Nov. 30 |
Michelle Long
ADM | Chief Administrative Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Gary Phillips
BRD | Director/Board Member | 62 | 22-06-30 |
Elizabeth Stoner
BRD | Director/Board Member | 73 | 21-11-09 |
Thomas Duthy
CHM | Chairman | - | 23-03-12 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-29 | 0.12 | +4.35% | 1 413 480 |
24-05-28 | 0.115 | 0.00% | 2,664,324 |
24-05-27 | 0.115 | -4.17% | 250,368 |
24-05-24 | 0.12 | +9.09% | 1,089,528 |
24-05-23 | 0.11 | +4.76% | 2,549,608 |
Delayed Quote Australian S.E., May 29, 2024 at 02:10 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.35% | 80.44M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.91% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- ALA Stock